FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308133021> ?p ?o ?g. }

• W4308133021 endingPage "A197" @default.
• W4308133021 startingPage "A196" @default.
• W4308133021 abstract "Abstract Introduction Osteoporosis, the most common bone disorder worldwide, is associated with increased morbidity and mortality. Available treatments include antiresorptive agents and anabolic therapies. Anabolic therapies are indicated in patients at high risk of osteoporotic fracture. There are challenges to utilizing anabolic therapies, however, including providing training on injection technique, addressing patient concerns about medication safety, and completion of medication prior authorizations. Pharmacist involvement could help ensure the safe and effective use of anabolic therapy. Objective To describe the 4-year, real-world results of a pharmacist-run abaloparatide osteoporosis clinic. Methods The primary study endpoint was the comparison of DXA T-scores and BMD values of the total hip, femoral neck, spine, and 1/3 radius (wrist) at baseline, after abaloparatide therapy, and following 1 year of follow-up antiresorptive therapy. The secondary end point was the number of documented fractures. Each patient served as his/her own control. Paired T-tests were performed to compare mean differences in pre- and post- T-scores and BMD values. Results Between April 2017 and October 2021, 146 patients were referred for abaloparatide therapy, with 91 patients (62.3%) initiating therapy. Eighteen patients refused to begin therapy because of concerns of adverse drug reactions, lack of interest in treating their osteoporosis, or because of the route of drug administration. Other consenting patients did not initiate therapy due to high monthly co-pay costs (15), insurance preferring teriparatide (1), insurance refusing coverage of any anabolic therapy (1), and contraindication to abaloparatide therapy (10). The average age at initiation of therapy was 66.7 (+ 7.7) years, 97.8% were women, 98.9% were Caucasian, mean BMI was 25.2 (+ 6.0), 56% had a history of osteoporotic fracture, baseline T-Scores of the femoral neck and spine were -2.5 (+ 0.7), and -2.4 (+ 1.3), respectively, and 49.5% of patients were osteoporosis drug naïve. There were significant improvements in T-scores and BMD at the spine, total hip and femoral neck during an average of 12 + 2 months (range 9–18 months) of abaloparatide therapy, and a significant decrease in T-score at the 1/3 radius. All patients received follow-up antiresorptive therapy, with 84.1% of patients receiving denosumab. After 1 year of antiresorptive therapy, significant increases in T-scores and BMD were seen at the total hip and lumbar spine, with nonsignificant changes in the femoral neck and 1/3 radius. There was one reported fracture during the evaluation period. Eighteen patients (19.8%) discontinued therapy due to an ADR. Conclusion Abaloparatide is effective in increasing BMD and T-scores and in preventing osteoporosis-related fractures. The fact that 37.7% of referred patients did not initiate therapy, indicates that significant barriers to anabolic osteoporosis treatment remain. Noteworthy, however, is the achieved 72.5% persistence rate of the patients initiating abaloparatide at this pharmacist-run anabolic osteoporosis clinic. Presentation: Saturday, June 11, 2022 1:00 p.m. - 3:00 p.m." @default.
• W4308133021 created "2022-11-08" @default.
• W4308133021 creator A5010133839 @default.
• W4308133021 creator A5012286605 @default.
• W4308133021 creator A5024439697 @default.
• W4308133021 creator A5035039255 @default.
• W4308133021 creator A5057351007 @default.
• W4308133021 creator A5072964190 @default.
• W4308133021 date "2022-11-01" @default.
• W4308133021 modified "2023-10-05" @default.
• W4308133021 title "PSAT156 Abaloparatide Implementation and Follow-Up: Real-World Results of a Pharmacist-Run Anabolic Osteoporosis Clinic" @default.
• W4308133021 doi "https://doi.org/10.1210/jendso/bvac150.404" @default.
• W4308133021 hasPublicationYear "2022" @default.
• W4308133021 type Work @default.
• W4308133021 citedByCount "0" @default.
• W4308133021 crossrefType "journal-article" @default.
• W4308133021 hasAuthorship W4308133021A5010133839 @default.
• W4308133021 hasAuthorship W4308133021A5012286605 @default.
• W4308133021 hasAuthorship W4308133021A5024439697 @default.
• W4308133021 hasAuthorship W4308133021A5035039255 @default.
• W4308133021 hasAuthorship W4308133021A5057351007 @default.
• W4308133021 hasAuthorship W4308133021A5072964190 @default.
• W4308133021 hasBestOaLocation W43081330211 @default.
• W4308133021 hasConcept C104863432 @default.
• W4308133021 hasConcept C126322002 @default.
• W4308133021 hasConcept C142724271 @default.
• W4308133021 hasConcept C1862650 @default.
• W4308133021 hasConcept C187212893 @default.
• W4308133021 hasConcept C197934379 @default.
• W4308133021 hasConcept C203092338 @default.
• W4308133021 hasConcept C204787440 @default.
• W4308133021 hasConcept C2776494729 @default.
• W4308133021 hasConcept C2776541429 @default.
• W4308133021 hasConcept C2776886416 @default.
• W4308133021 hasConcept C2777308945 @default.
• W4308133021 hasConcept C2779457091 @default.
• W4308133021 hasConcept C512399662 @default.
• W4308133021 hasConcept C535046627 @default.
• W4308133021 hasConcept C71924100 @default.
• W4308133021 hasConceptScore W4308133021C104863432 @default.
• W4308133021 hasConceptScore W4308133021C126322002 @default.
• W4308133021 hasConceptScore W4308133021C142724271 @default.
• W4308133021 hasConceptScore W4308133021C1862650 @default.
• W4308133021 hasConceptScore W4308133021C187212893 @default.
• W4308133021 hasConceptScore W4308133021C197934379 @default.
• W4308133021 hasConceptScore W4308133021C203092338 @default.
• W4308133021 hasConceptScore W4308133021C204787440 @default.
• W4308133021 hasConceptScore W4308133021C2776494729 @default.
• W4308133021 hasConceptScore W4308133021C2776541429 @default.
• W4308133021 hasConceptScore W4308133021C2776886416 @default.
• W4308133021 hasConceptScore W4308133021C2777308945 @default.
• W4308133021 hasConceptScore W4308133021C2779457091 @default.
• W4308133021 hasConceptScore W4308133021C512399662 @default.
• W4308133021 hasConceptScore W4308133021C535046627 @default.
• W4308133021 hasConceptScore W4308133021C71924100 @default.
• W4308133021 hasIssue "Supplement_1" @default.
• W4308133021 hasLocation W43081330211 @default.
• W4308133021 hasLocation W43081330212 @default.
• W4308133021 hasOpenAccess W4308133021 @default.
• W4308133021 hasPrimaryLocation W43081330211 @default.
• W4308133021 hasRelatedWork W1986309721 @default.
• W4308133021 hasRelatedWork W2057064011 @default.
• W4308133021 hasRelatedWork W2148557216 @default.
• W4308133021 hasRelatedWork W2237583720 @default.
• W4308133021 hasRelatedWork W2553653699 @default.
• W4308133021 hasRelatedWork W26870813 @default.
• W4308133021 hasRelatedWork W3162653190 @default.
• W4308133021 hasRelatedWork W3167375877 @default.
• W4308133021 hasRelatedWork W4308133021 @default.
• W4308133021 hasRelatedWork W2395390382 @default.
• W4308133021 hasVolume "6" @default.
• W4308133021 isParatext "false" @default.
• W4308133021 isRetracted "false" @default.
• W4308133021 workType "article" @default.